Previous Close | 12.900 |
Open | 12.780 |
Bid | 12.740 x 0 |
Ask | 12.760 x 0 |
Day's Range | 12.600 - 13.200 |
52 Week Range | 12.420 - 52.450 |
Volume | |
Avg. Volume | 68,872,135 |
Market Cap | 53.032B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | 15.35 |
EPS (TTM) | 0.830 |
Earnings Date | Mar 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.75 |
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environmental non-profit CDP, achieving the Leadership level with a score of "A-".